Get the Stockscreener App
112.50
2.45%
-2.83
After Hours:
112.50
Overview
News
Price History
Option Chain
Financials
Why RVTY Down?
Discussions
Forecast
Stock Split
Dividend History
Revvity Inc stock is traded at $112.50, with a volume of 1.60M.
It is down -2.45% in the last 24 hours and up +16.86% over the past month.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
See More
Previous Close:
$115.33
Open:
$114.83
24h Volume:
1.60M
Relative Volume:
1.12
Market Cap:
$12.75B
Revenue:
$2.77B
Net Income/Loss:
$286.61M
P/E Ratio:
47.87
EPS:
2.35
Net Cash Flow:
$524.11M
1W Performance:
+7.73%
1M Performance:
+16.86%
6M Performance:
+18.55%
1Y Performance:
-5.88%
1-Day Range:
$111.86
$115.44
1-Week Range:
$102.71
$115.78
52-Week Range:
$81.36
$128.28
Revvity Inc Stock (RVTY) Company Profile
Name
Revvity Inc
Sector
Industry
Phone
781-663-6900
Address
77 4TH AVENUE, WALTHAM
Compare RVTY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
112.50 | 13.08B | 2.77B | 286.61M | 524.11M | 2.35 |
|
TMO
Thermo Fisher Scientific Inc
|
618.72 | 234.69B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.99 | 169.45B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
715.37 | 56.86B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
237.68 | 41.09B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
139.64 | 41.06B | 6.95B | 1.30B | 1.15B | 4.5696 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-25 | Initiated | Goldman | Neutral |
| Oct-16-25 | Initiated | Guggenheim | Neutral |
| May-01-25 | Upgrade | UBS | Neutral → Buy |
| Jan-10-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-15-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-08-24 | Initiated | Leerink Partners | Outperform |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | UBS | Buy → Neutral |
| Jan-04-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-23-23 | Resumed | Goldman | Buy |
View All
Revvity Inc Stock (RVTY) Latest News
Surprises Report: Can Revvity Inc outperform in the next rallyJuly 2025 Spike Watch & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
How is Revvity's stock performance compared to other health care stocks? - MSN
Revvity Stock Gains On Solid Early Q4 Results, Upbeat Outlook - Sahm
The Bull Case For Revvity (RVTY) Could Change Following Upbeat 2025 Guidance And New Lilly AI Alliance - Yahoo Finance
What's Going On With Revvity Stock Wednesday?Revvity (NYSE:RVTY) - Benzinga
Weekly Trades: Is Revvity Inc showing insider buyingPortfolio Update Summary & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Revvity stock surges on exceeding profit forecasts - MSN
How (RVTY) Movements Inform Risk Allocation Models - Stock Traders Daily
Revvity (NYSE:RVTY) Shares Gap UpHere's Why - MarketBeat
Revvity expects to report Q4 revenue of $772 million - MSN
Revvity Inc expects existing end market trends to continue into 2026presentation - marketscreener.com
Risk Hedge: What dividend safety score for Revvity Inc stock2025 Trade Ideas & Risk Adjusted Buy/Sell Alerts - Bộ Nội Vụ
Revvity Raises 2025 Outlook With Strong Preliminary Results - TipRanks
Revvity Inc Expect Existing End Market Trends To Continue Into 2026Presentation - TradingView — Track All Markets
Stock Market Today: Nasdaq 100, S&P 500, Dow Jones Futures Lag Ahead Of December CPI Print— JPMorgan, Alphabet, Five9 In Focus (UPDATED) - Benzinga
S&P 500 Futures Decline in Premarket Trading; L3Harris Technologies, Revvity Lead - Barron's
Revvity (NYSE:RVTY) Issues FY 2025 Earnings Guidance - MarketBeat
Revvity Stock Pre-Market (+4.9%): Exceeds Top-End of EPS and Revenue Guidance - Trefis
Why Is RVTY Stock Surging in Premarket? Q4 Revenue Outlook Tops Expectations - Tokenist
Revvity Stock Jumps on Profit Outlook Hike. Why the Shares Are at a Crossroads. - Barron's
Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance - PharmiWeb.com
Revvity says it will exceed 2025 profit forecast range - MSN
Revvity sale, perché la società prevede di superare le previsioni di profitto per il 2025 - TradingView — Track All Markets
Revvity rises as co expects to exceed 2025 profit forecast - TradingView — Track All Markets
Revvity Preliminary Q4 Revenue Tops Estimates; Shares Rise After Hours - marketscreener.com
RVTY Stock Shows Positive Outlook with Analyst Consensus - GuruFocus
Revvity (RVTY) Sees Stock Uptick After Q4 Revenue Announcement - GuruFocus
RVTY Projects Revenue Growth for Q4 and 2025 - GuruFocus
Revvity expects to exceed Q4 guidance with 6% revenue growth - Investing.com
Revvity expects to exceed Q4 guidance with 6% revenue growth By Investing.com - Investing.com India
RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models - TradingView — Track All Markets
Revvity collaborates with Eli Lilly to expand access to AI drug discovery models - BioSpectrum Asia
Why Revvity (RVTY) Is Up 6.4% After New Lilly AI Drug Discovery Partnership Integration - simplywall.st
Revvity's (NYSE:RVTY) Earnings Trajectory Could Turn Positive as the Stock Climbs 6.4% This Past Week - 富途牛牛
Revvity and Lilly partner to accelerate AI drug discovery models - Indian Pharma Post
About Us | Laser Focus WorldRevvity, Inc. Common Stock (NYSE:RVTY) Price Chart - FinancialContent
Key facts: Eli Lilly to acquire Ventyx for $1.2B; Mounjaro pricing in India; AI partnership with Revvity - TradingView — Track All Markets
Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models - PharmiWeb.com
Revvity, Inc. Collaborates with Eli Lilly and Company to Expand Access to Ai Drug Discovery Models - marketscreener.com
Eli Lilly in pact with Schrödinger, Revvity for AI-driven drug discovery - Seeking Alpha
Revvity collaborates with Lilly to expand access to AI drug discovery models - marketscreener.com
Revvity announces collaboration with Eli Lilly on AI drug discovery models - TipRanks
Revvity, Lilly Partner To Expand Access To AI Drug Discovery Models - Nasdaq
Revvity (NYSE:RVTY) earnings and shareholder returns have been trending downwards for the last five years, but the stock lifts 5.1% this past week - simplywall.st
Will Revvity Inc. (PKN) stock outperform global peersJuly 2025 Action & High Conviction Investment Ideas - ulpravda.ru
Can Revvity Inc. (PKN) stock ride next bull market cycle2025 Volume Leaders & High Conviction Trade Alerts - ulpravda.ru
Is Revvity Inc. stock a good choice for value investorsJuly 2025 Short Interest & High Yield Equity Trading Tips - ulpravda.ru
Revvity Inc. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛
Is Revvity Inc. (PKN) stock a buy on weakness2025 Retail Activity & Free Risk Controlled Daily Trade Plans - ulpravda.ru
Will Revvity Inc. stock reach all time highs in 2025Market Risk Report & Weekly Watchlist for Hot Stocks - ulpravda.ru
Revvity Inc. Stock Underperforms Wednesday When Compared To Competitors - 富途牛牛
Revvity Inc Stock (RVTY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):